The Pilot and Feasibility Program is directed by Atul Bhan. In this role, Dr. Bhan will evaluate letters of intent for suitability, assist the Center director with identification of appropriate reviewers, and examine reviews received. Dr. Bhan is charged specifically with reviewing these initial funding proposals in the context of the overall programmatic goals of the Center in fostering new digestive disease investigators and advancing understanding of IBD. He will also chair the meeting of the CSIBD Executive Steering Committee that ranks the proposals for funding.
The specific aims of the Pilot and Feasibility Program are to (1) recruit new investigators into IBD research by providing funding for IBD related nascent research programs, and (2) generate new ideas related to IBD research by providing funding for innovative high risk high payoff lines of investigation. As detailed in the Research Strategy of this program, achievement of these goals is evident in the success that P/F recipients have had in bringing pilot projects to the juncture at which they have led to ongoing research funding by external peer-reviewed agencies as well as results warranting publication in peer-reviewed journals. In the last ten years of funding (2005-2014), 35 Pilot and Feasibility Program award recipients have gone on to become independent investigators; 10 of these transitions to independence occurred since the last competing renewal in 2009.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
2P30DK043351-26
Application #
8972395
Study Section
Special Emphasis Panel (ZDK1)
Project Start
1997-01-01
Project End
2020-12-31
Budget Start
2016-03-15
Budget End
2016-12-31
Support Year
26
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
Qu, Chen; Zheng, Dandan; Li, Sai et al. (2018) Tyrosine kinase SYK is a potential therapeutic target for liver fibrosis. Hepatology :
Simon, Tracey G; King, Lindsay Y; Chong, Dawn Q et al. (2018) Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: Results from two prospective cohort studies. Hepatology 67:1797-1806
Borren, Nienke Z; Conway, Grace; Garber, John J et al. (2018) Differences in Clinical Course, Genetics, and the Microbiome Between Familial and Sporadic Inflammatory Bowel Diseases. J Crohns Colitis 12:525-531
Battistone, Maria A; Nair, Anil V; Barton, Claire R et al. (2018) Extracellular Adenosine Stimulates Vacuolar ATPase-Dependent Proton Secretion in Medullary Intercalated Cells. J Am Soc Nephrol 29:545-556
Imhann, Floris; Vich Vila, Arnau; Bonder, Marc Jan et al. (2018) Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease. Gut 67:108-119
Chandradas, Sajiv; Khalili, Hamed; Ananthakrishnan, Ashwin et al. (2018) Does Obesity Influence the Risk of Clostridium difficile Infection Among Patients with Ulcerative Colitis? Dig Dis Sci 63:2445-2450
Luther, Jay; Gala, Manish; Patel, Suraj J et al. (2018) Loss of Response to Anti-Tumor Necrosis Factor Alpha Therapy in Crohn's Disease Is Not Associated with Emergence of Novel Inflammatory Pathways. Dig Dis Sci 63:738-745
Graham, Daniel B; Luo, Chengwei; O'Connell, Daniel J et al. (2018) Antigen discovery and specification of immunodominance hierarchies for MHCII-restricted epitopes. Nat Med 24:1762-1772
Schirmer, Melanie; Franzosa, Eric A; Lloyd-Price, Jason et al. (2018) Dynamics of metatranscription in the inflammatory bowel disease gut microbiome. Nat Microbiol 3:337-346
Cheung, Pui W; Terlouw, Abby; Janssen, Sam Antoon et al. (2018) Inhibition of non-receptor tyrosine kinase Src induces phosphoserine 256-independent aquaporin-2 membrane accumulation. J Physiol :

Showing the most recent 10 out of 1166 publications